Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTH522
- Development stage
- Phase 1
- Lead developer
- Statens Serum Institut
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Intradermal, Topical, Ophthalmic
01
Overview
CTH522 is an investigational recombinant protein-subunit vaccine developed by Statens Serum Institut to prevent *Chlamydia trachomatis* infection, including genital chlamydia and trachoma. The engineered antigen is based on *C. trachomatis* major outer membrane protein and incorporates heterologous variable-domain immunorepeats from genital serovars D, E, F, and G. It is intended to elicit MOMP-specific neutralizing antibodies and cellular immune responses; clinical formulations have included the CAF01 liposomal adjuvant, aluminum hydroxide, and CAF09b. CTH522 completed Phase I clinical testing in genital-chlamydia and trachoma-oriented studies, with reported acceptable safety and immunogenicity findings. ([thelancet.com](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2819%2930279-8/fulltext))
- Other names
- SSI's adjuvanted chlamydia vaccineCTH522-CAF01CTH-522-CAF01CTH 522-CAF01CTH522-Al(OH)3
02
Targets
MOMP (Major outer membrane protein)
Beyond the preview
Go deeper on CTH522.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTH522.